HODGKINS LYMPHOMA TREATMENT MARKET ANALYSIS

Lymphoma is a cancer caused in lymphocytes of the body, i.e. white blood cells. It is of two types – Hodgkin’s Lymphoma and Non-Hodgkin’s Lymphoma. Hodgkin’s Lymphoma can be characterized into two categories – classic and nodular lymphocyte predominant. Some of the signs indicating presence of Hodgkin’s Lymphoma in the body is fever, sudden weight loss, and swollen lymph nodes. Hodgkin’s Lymphoma is mostly treated with chemotherapy alone or with the combination of radiotherapy.

Global Hodgkin’s Lymphoma Treatment Market Drivers

Approvals of the drugs by regulatory bodies for the treatment of Hodgkin’s lymphoma is expected to drive the global Hodgkin’s lymphoma market growth. In 2018, Seattle Genetics, Inc. received the Health Canada approval for its supplemental New Drug Submission that expands the use of Adcetris (brentuximab vedotin) in combination with AVD (Adriamycin, vinblastine and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Furthermore, key players are constantly trying to expand the indications of their already approved drug. For instance, in March 2017, Merck & Co. Inc. received an approval by U.S. Food & Drug Administration (FDA) of the drug, Keytruda for the treatment of classical Hodgkin’s lymphoma. It is approved on the basis of response durability and tumor response rate and is supposed to be administered intravenously into patients. It was originally approved in 2014. Such frequent approvals of drugs by regulatory bodies are expected to impact positively on the global Hodgkin’s lymphoma treatment market growth.

Global Hodgkin’s Lymphoma Treatment Market Regional Analysis

North America is expected to hold a dominant position in the global Hodgkin’s lymphoma market over the forecast period. Frequent research and development activities done by the government and other organizations is expected to drive the North America Hodgkin’s lymphoma treatment market growth. For instance, in December 2016, Ohio State University Comprehensive Cancer Center and National Cancer Institute (NCI) commenced a U.S. FDA clinical trial of Ibrutinib in combination with Nivolumab, in the patients suffering from classical Hodgkin’s Lymphoma, in the U.S to study its efficacy. Ibritunib may block the cancer cell growth by blocking the enzymes responsible for growth and Nivolumab may block cancer cells by targeting different cells. Currently, it’s in the second phase of clinical trials. The study involves 17 participants and is estimated to be completed by 2020.

Furthermore, various outside organizations are involved in research and development activities for development and gaining the U.S. FDA approval of novel Hodgkin’s lymphoma treatment drug in the U.S.

For instance, in September 2017, Chinese PLA General Hospital, a Chinese government organization, commenced its clinical trial of Decitabine in combination with SHR – 1210. It is being used for the treatment of Hodgkin’s lymphoma. SHR – 1210 is a monoclonal antibody, while Decitabine is an investigational drug, which is capable of boosting antigen expression. The clinical study is for analyzing the safety and efficacy of the drugs. Currently, it is in the second phase of clinical trials.

Global Hodgkin’s Lymphoma Treatment Market Restraints

Side effects related with drugs used for the treatment of Hodgkin’s lymphoma is expected to adversely affect adoption of these drugs, thereby hindering the global Hodgkin’s lymphoma treatment market growth. For instance, according to American Cancer Society, drugs used for treating Hodgkin’s lymphoma such as doxorubicin and bleomycin can damage heart and lungs respectively. Hence, such side effects of drugs can hinder the global Hodgkin’s lymphoma treatment market growth.

Global Hodgkin’s Lymphoma Treatment Market Key Players

Some of the major players operating in the global Hodgkin’s lymphoma treatment market include Emcure Pharmaceuticals Pvt. Ltd., Aspen Global Inc., Pfizer Inc., Ono Pharmaceuticals Co. Ltd., Corden Pharma Latina SPA, Horizon Pharma USA Inc., Cipla Ltd., Lediant Biosciences Inc., Jansenn Research and Development LLC, and Merck & Co., Inc.

Global Hodgkin’s Lymphoma Treatment Market Taxonomy

The global Hodgkin’s lymphoma treatment market is segmented on the basis of treatment type, route of administration, distribution channel, and regions. 

By Treatment Type

• Immunotherapy
• Monoclonal Antibody
  • Conjugated
    • Brentuximab Vedotin
  • Non-conjugated
    • Nivolumab
    • Pembrolizumab
    • Brentuximab
  • Chemotherapy
  • Others

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa